Cytarabine

Generic Name
Cytarabine
Brand Names
Cytosar, Vyxeos
Drug Type
Small Molecule
Chemical Formula
C9H13N3O5
CAS Number
147-94-4
Unique Ingredient Identifier
04079A1RDZ
Background

A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra P...

Indication

For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
...

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Associated Therapies
-
Clinical Trials
Related News

S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma

First Posted Date
2003-01-27
Last Posted Date
2012-11-01
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
56
Registration Number
NCT00041132

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Aggressive Non-Hodgkin's Lymphoma

Phase 3
Completed
Conditions
Lymphoma
First Posted Date
2003-01-27
Last Posted Date
2012-05-15
Lead Sponsor
Swiss Group for Clinical Cancer Research
Target Recruit Count
400
Registration Number
NCT00003215
Locations
🇨🇭

Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

🇨🇭

Inselspital, Bern, Bern, Switzerland

🇨🇭

Ratisches Kantons und Regionalspital, Chur, Switzerland

and more 9 locations

Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia

First Posted Date
2003-01-27
Last Posted Date
2013-01-23
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
60
Registration Number
NCT00023920
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

First Posted Date
2003-01-27
Last Posted Date
2013-01-16
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
100
Registration Number
NCT00016302
Locations
🇺🇸

Children's Oncology Group, Arcadia, California, United States

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Phase 3
Completed
Conditions
Childhood Acute Erythroleukemia (M6)
Childhood Acute Megakaryocytic Leukemia (M7)
Childhood Acute Monoblastic Leukemia (M5a)
Childhood Acute Monocytic Leukemia (M5b)
Childhood Acute Myeloblastic Leukemia With Maturation (M2)
Childhood Acute Myeloblastic Leukemia Without Maturation (M1)
Childhood Acute Myelomonocytic Leukemia (M4)
Childhood Myelodysplastic Syndromes
Chronic Myelomonocytic Leukemia
de Novo Myelodysplastic Syndromes
Interventions
Drug: daunorubicin hydrochloride
Drug: asparaginase
Drug: therapeutic hydrocortisone
Radiation: 3-dimensional conformal radiation therapy
Drug: fludarabine phosphate
Procedure: allogeneic bone marrow transplantation
Biological: filgrastim
Drug: cytarabine
Drug: idarubicin
Drug: dexamethasone
Biological: aldesleukin
Drug: thioguanine
Drug: etoposide
Drug: methotrexate
Drug: cyclophosphamide
Drug: busulfan
First Posted Date
2003-01-27
Last Posted Date
2013-01-16
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
880
Registration Number
NCT00002798
Locations
🇺🇸

Children's Oncology Group, Arcadia, California, United States

Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer

First Posted Date
2003-01-27
Last Posted Date
2016-01-22
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
32
Registration Number
NCT00014495
Locations
🇺🇸

Memorial Sloan - Kettering Cancer Center, New York, New York, United States

Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia

First Posted Date
2003-01-27
Last Posted Date
2023-07-05
Lead Sponsor
Eastern Cooperative Oncology Group
Target Recruit Count
449
Registration Number
NCT00046930
Locations
🇺🇸

Evanston Northwestern Health Care - Evanston Hospital, Evanston, Illinois, United States

🇺🇸

CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States

🇺🇸

Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin, United States

and more 88 locations

S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia

Phase 2
Completed
Conditions
Leukemia
First Posted Date
2003-01-27
Last Posted Date
2015-03-06
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
33
Registration Number
NCT00049179
Locations
🇺🇸

Charles B. Eberhart Cancer Center at DeKalb Medical Center, Decatur, Georgia, United States

🇺🇸

Kennestone Cancer Center at Wellstar Kennestone Hospital, Marietta, Georgia, United States

🇺🇸

David C. Pratt Cancer Center at St. John's Mercy, St. Louis, Missouri, United States

and more 148 locations

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia

First Posted Date
2003-01-27
Last Posted Date
2023-06-15
Lead Sponsor
Eastern Cooperative Oncology Group
Target Recruit Count
657
Registration Number
NCT00049517
Locations
🇺🇸

Community Medical Center, Missoula, Montana, United States

🇺🇸

Penn State Cancer Institute at Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States

🇺🇸

Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States

and more 96 locations

T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic Anemia

First Posted Date
2003-01-27
Last Posted Date
2015-12-23
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
31
Registration Number
NCT00002718
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy